Knowledge of the cardiac safety of emerging new drugs is an important aspect of assuring the expeditious advancement of the best candidates targeted at unmet medical needs while also assuring the safety of clinical trial subjects or patients.
Health and Environmental Sciences Institute (HESI) Initiative on Moving Towards Better Predictors of Drug‐Induced Torsades de Pointes
British Journal of Pharmacology, 2008